EUR 7.17
(-1.38%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 2.22 Million EUR | -87.83% |
2022 | 18.3 Million EUR | -30.43% |
2021 | 26.3 Million EUR | 152.51% |
2020 | 10.41 Million EUR | -59.86% |
2019 | 25.95 Million EUR | 6.12% |
2018 | 24.45 Million EUR | 266.0% |
2017 | 6.68 Million EUR | 1644.65% |
2016 | 383 Thousand EUR | 9475.0% |
2015 | 4000.00 EUR | 0.0% |
2014 | - EUR | 0.0% |
2013 | - EUR | 0.0% |
2012 | - EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 69.04 Million EUR | 0.0% |
2023 Q2 | 1.35 Million EUR | 0.0% |
2023 Q4 | 869 Thousand EUR | 0.0% |
2023 FY | 2.22 Million EUR | -87.83% |
2022 Q2 | 16.04 Million EUR | 0.0% |
2022 Q4 | 2.25 Million EUR | 0.0% |
2022 FY | 18.3 Million EUR | -30.43% |
2021 FY | 26.3 Million EUR | 152.51% |
2021 Q4 | 17.33 Million EUR | 0.0% |
2021 Q2 | 8.97 Million EUR | 0.0% |
2020 Q4 | 4.56 Million EUR | 0.0% |
2020 FY | 10.41 Million EUR | -59.86% |
2020 Q2 | 5.84 Million EUR | 0.0% |
2019 Q4 | 9.97 Million EUR | 0.0% |
2019 Q2 | 15.97 Million EUR | 0.0% |
2019 FY | 25.95 Million EUR | 6.12% |
2018 FY | 24.45 Million EUR | 266.0% |
2018 Q2 | 20.6 Million EUR | 0.0% |
2018 Q4 | 3.84 Million EUR | 0.0% |
2017 FY | 6.68 Million EUR | 1644.65% |
2017 Q4 | 3.83 Million EUR | 0.0% |
2017 Q2 | 2.84 Million EUR | 0.0% |
2016 FY | 383 Thousand EUR | 9475.0% |
2016 Q4 | 344 Thousand EUR | 0.0% |
2016 Q2 | 39 Thousand EUR | 0.0% |
2015 FY | 4000.00 EUR | 0.0% |
2015 Q4 | 3000.00 EUR | 0.0% |
2015 Q2 | 1000.00 EUR | 0.0% |
2014 FY | - EUR | 0.0% |
2014 Q4 | - EUR | 0.0% |
2014 Q2 | - EUR | 0.0% |
2013 Q1 | - EUR | 0.0% |
2013 Q2 | - EUR | 0.0% |
2013 Q3 | - EUR | 0.0% |
2013 FY | - EUR | 0.0% |
2013 Q4 | - EUR | 0.0% |
2012 FY | - EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
ABIONYX Pharma SA | 4.64 Million EUR | 52.004% |
ABIVAX Société Anonyme | 4.62 Million EUR | 51.807% |
Adocia SA | 2.15 Million EUR | -3.581% |
Aelis Farma SA | 9.05 Million EUR | 75.403% |
Biophytis S.A. | - EUR | -Infinity% |
Advicenne S.A. | 3.15 Million EUR | 29.324% |
genOway Société anonyme | 20.04 Million EUR | 88.891% |
IntegraGen SA | 12.53 Million EUR | 82.237% |
Medesis Pharma S.A. | 300.03 Thousand EUR | -642.249% |
Neovacs S.A. | 533.41 Thousand EUR | -317.501% |
NFL Biosciences SA | - EUR | -Infinity% |
Plant Advanced Technologies SA | 1.68 Million EUR | -32.44% |
Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -11149.747% |
Sensorion SA | 4.74 Million EUR | 53.047% |
Theranexus Société Anonyme | 296.33 Thousand EUR | -651.524% |
TME Pharma N.V. | 17 Thousand EUR | -13000.0% |
Valbiotis SA | 4.73 Million EUR | 52.947% |
TheraVet SA | 1.07 Million EUR | -106.576% |
Valerio Therapeutics Société anonyme | 1.8 Million EUR | -23.722% |
argenx SE | 1.13 Billion EUR | 99.804% |
BioSenic S.A. | 543 Thousand EUR | -310.129% |
Celyad Oncology SA | 102 Thousand EUR | -2083.333% |
DBV Technologies S.A. | - EUR | -Infinity% |
Galapagos NV | 239.72 Million EUR | 99.071% |
Genfit S.A. | 28.56 Million EUR | 92.204% |
GeNeuro SA | - EUR | -Infinity% |
Hyloris Pharmaceuticals SA | 2.08 Million EUR | -6.708% |
Innate Pharma S.A. | 51.9 Million EUR | 95.709% |
Inventiva S.A. | 17.47 Million EUR | 87.258% |
MaaT Pharma SA | 2.22 Million EUR | 0.045% |
MedinCell S.A. | 9.16 Million EUR | 75.688% |
Nanobiotix S.A. | 30.05 Million EUR | 92.591% |
Onward Medical N.V. | 532 Thousand EUR | -318.609% |
Oryzon Genomics S.A. | 14.19 Million EUR | 84.308% |
Oxurion NV | 263 Thousand EUR | -746.768% |
Pharming Group N.V. | 245.31 Million EUR | 99.092% |
Poxel S.A. | 1.98 Million EUR | -12.418% |
GenSight Biologics S.A. | 1.26 Million EUR | -75.77% |
Transgene SA | 1.18 Million EUR | -88.091% |
Financière de Tubize SA | - EUR | -Infinity% |
UCB SA | 5.25 Billion EUR | 99.958% |
Valneva SE | 153.71 Million EUR | 98.551% |
Vivoryon Therapeutics N.V. | -3.62 Million EUR | 161.519% |